Discovery of CC-90003: A covalent ERK1/2 inhibitor

被引：0
|
作者：
Qiao, Li-Xin [1 ]
机构：
[1] Celgene Corp, Cambridge, MA USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2017年 / 254卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
26
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Discovery of a Novel Covalent ADAR1 Inhibitor
    Wang, C.
    McKinney, A.
    Marcolino, M.
    Quanrud, G.
    Dong, I.
    Chen, A.
    Deng, N.
    Guo, S.
    Jansa, P.
    Yuan, I.
    Cao, P.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S164 - S164
  • [32] Discovery of novel photocaged ERK1/2 inhibitors as light-controlled anticancer agents
    Chen, Rui
    Wang, Ziyue
    Liu, Lihong
    Pan, Zhengying
    CHEMICAL COMMUNICATIONS, 2022, 58 (31) : 4901 - 4904
  • [33] Effects of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation and cell survival in glioma cells
    Jin, Lei
    Cao, Yujia
    Zhang, Tong
    Wang, Peng
    Ji, Daofei
    Liu, Xuejiao
    Shi, Hengliang
    Hua, Lei
    Yu, Rutong
    Gao, Shangfeng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 41 (03) : 1339 - 1348
  • [34] ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1
    Balmanno, Kathryn
    Kidger, Andrew M.
    Byrne, Dominic P.
    Sale, Matthew J.
    Nassman, Nejma
    Eyers, Patrick A.
    Cook, Simon J.
    BIOCHEMICAL JOURNAL, 2023, 480 (09) : 587 - 605
  • [35] Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC
    Simpson, Iain
    Anderton, Mark J.
    Andrews, David M.
    Breed, Jason
    Davies, Emma
    Debreczeni, Judit E.
    Flemington, Vikki
    Gibbons, Francis D.
    Graham, Mark A.
    Hopcroft, Philip
    Howard, Tina
    Hudson, Julian
    Jones, Clifford D.
    Jones, Christopher
    Lindsay, Nicola
    Pease, J. Elizabeth
    Rawlins, Philip
    Roberts, Karen
    Swallow, Steve
    St-Gallay, Steve
    Tonge, Michael E.
    Ward, Richard A.
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
    Bhagwat, Shripad V.
    McMillen, William T.
    Cai, Shufen
    Zhao, Baohui
    Whitesell, Matthew
    Kindler, Lisa
    Flack, Robert S.
    Wu, Wenjuan
    Huss, Karen
    Anderson, Bryan
    Yuan, Xiu-Juan
    Jaken, Susan
    McCann, Denis
    Mathes, Brian
    Dropsey, Andrew J.
    Manro, Jason
    Walgren, Jennie
    Yuen, Eunice
    Gong, Xueqian
    Rodriguez, Michael J.
    Huang, Jianping
    Tiu, Ramon V.
    Joseph, Sajan
    Peng, Sheng-Bin
    CANCER RESEARCH, 2017, 77
  • [37] Navigating the ERK1/2 MAPK Cascade
    Martin-Vega, Ana
    Cobb, Melanie H.
    BIOMOLECULES, 2023, 13 (10)
  • [38] A novel mechanism of ERK1/2 regulation in smooth muscle involving acetylation of the ERK1/2 scaffold IQGAP1
    Susanne Vetterkind
    Qian Qian Lin
    Kathleen G. Morgan
    Scientific Reports, 7
  • [39] A novel mechanism of ERK1/2 regulation in smooth muscle involving acetylation of the ERK1/2 scaffold IQGAP1
    Vetterkind, Susanne
    Lin, Qian Qian
    Morgan, Kathleen G.
    SCIENTIFIC REPORTS, 2017, 7
  • [40] Repression of ERK1/2 signaling by RanBPM
    Atabakhsh, Elnaz
    Schild-Poulter, Caroline
    CANCER RESEARCH, 2011, 71
12345